CAJ | 학술논문

目的：观察埃克替尼与吉非替尼治疗表皮生长因子受体(epidermal growth factor receptor，EGFR)突变的晚期肺腺癌的疗效和不良反应。方法收集2012年1月-2014年6月我院56例EGFR突变的晚期肺腺癌患者，随机分为试验组和对照组，试验组口服盐酸埃克替尼，每次125 mg，3次/d，对照组口服吉非替尼，每次250 mg，1次/d，服用至少1个月后评价疗效及安全性。结果试验组28例中完全缓解(complete response，CR)0例，部分缓解(partial response，PR)11例，疾病稳定(stable disease，SD)7例，疾病进展(progressive disease，PD)10例，客观有效率(objective response rate，ORR)39.3%，疾病控制率(disease control rate，DCR)64.3%。对照组28例中CR 0例，PR 7例，SD 8例，PD 13例，ORR 25%，DCR 53.6%。两组的客观有效率和疾病控制率、疾病进展时间和总生存时间差异均无统计学意义。主要不良反应为皮疹、腹泻，试验组总体不良反应发生率低于对照组(P＜0.05)。结论埃克替尼与吉非替尼治疗EGFR突变的晚期肺腺癌疗效相似，但埃克替尼不良反应较轻，患者耐受性好。
목적：관찰애극체니여길비체니치료표피생장인자수체(epidermal growth factor receptor，EGFR)돌변적만기폐선암적료효화불량반응。방법수집2012년1월-2014년6월아원56례EGFR돌변적만기폐선암환자，수궤분위시험조화대조조，시험조구복염산애극체니，매차125 mg，3차/d，대조조구복길비체니，매차250 mg，1차/d，복용지소1개월후평개료효급안전성。결과시험조28례중완전완해(complete response，CR)0례，부분완해(partial response，PR)11례，질병은정(stable disease，SD)7례，질병진전(progressive disease，PD)10례，객관유효솔(objective response rate，ORR)39.3%，질병공제솔(disease control rate，DCR)64.3%。대조조28례중CR 0례，PR 7례，SD 8례，PD 13례，ORR 25%，DCR 53.6%。량조적객관유효솔화질병공제솔、질병진전시간화총생존시간차이균무통계학의의。주요불량반응위피진、복사，시험조총체불량반응발생솔저우대조조(P＜0.05)。결론애극체니여길비체니치료EGFR돌변적만기폐선암료효상사，단애극체니불량반응교경，환자내수성호。
Objective To investigate the clinical efficacy and toxicity of icotinib and gefitinib in advanced lung adenocarcinoma with EGFR mutation.Methods Clinical data about 56 patients with advanced lung adenocarcinoma admitted to our hospital from January 2012 to June 2014 were retrospectively analyzed. They were divided into icotinib group and gefitinib group randomly, and patients in icotinib group were treated with icotinib three times a day by 125 mg, patients in gefitinib group were treated with gefitinib once a day by 250 mg at least one month.Results In icotinib group, complete response (CR), partial response (PR), stable disease and progressive disease were achieved in 0, 11, 7 and 10 patients, respectively, with the objective response rate (ORR) of 39.3% and disease control rate (DCR) of 64.3%. In gefitinib group, complete response (CR), partial response (PR), stable disease and progressive disease were achieved in 0, 7, 8 and 13 patients, respectively, with the objective response rate (ORR) of 25% and disease control rate (DCR) of 53.6%. There was no significant difference between the two groups in ORR, DCR, TTP and OS. The main adverse reactions were rash and diarrhea, which were less occurred in icotinib group (P<0.05).ConclusionIcotinib and gefitinib have similar efficacy in advanced lung adenocarcinoma with EGFR mutation, however, the toxicity of icotinib is better tolerated and acceptable.